Aethlon Medical与North Immunology宣布达成合并协议。此次合并旨在加速推进一款针对特应性皮炎的新型IL-13×IL-18双特异性抗体的临床开发。
双方表示，这一战略整合将汇聚两家公司在免疫学与抗体工程领域的专长，有望为特应性皮炎患者带来更具针对性的治疗选择。IL-13与IL-18双靶点策略被认为可能在炎症通路调控上发挥协同作用，从而提升疗效。
合并后的实体将继续聚焦于该双特异性抗体的研发进程，并计划在后续阶段推进相关临床试验。此次交易的具体条款尚未完全披露，但双方管理层均对此次合并的前景表达了积极预期。
分析人士指出，特应性皮炎治疗领域竞争日趋激烈，差异化靶点组合或将成为未来药物研发的重要方向。Aethlon Medical与North Immunology的此番联手，或许能为该领域注入新的变量。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.